Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092427 - COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Publication Number WO/2020/092427
Publication Date 07.05.2020
International Application No. PCT/US2019/058648
International Filing Date 29.10.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • TIGATX, INC. [US]/[US]
  • UMC UTRECHT HOLDING B.V. [NL]/[NL]
Inventors
  • DE BOER, Mark
  • LEUSEN, Jeannette Henrica Wilhelmina
  • VAN TETERING, Geert Jan
Agents
  • VYAS, PAYAL V.
Priority Data
18203183.129.10.2018EP
62/752,64130.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS
(FR) COMPOSITIONS ET MÉTHODES COMPRENANT DES CONSTRUCTIONS D'ANTICORPS IGA
Abstract
(EN)
Provided herein are therapeutic agents, pharmaceutical compositions, and methods comprising an IgA constant region. The compositions and methods described herein facilitate binding of an antibody construct comprising an IgA constant domain to CD47 and an antigen for instance a tumor related antigen such as CD20 or CD19.
(FR)
L'invention concerne des agents thérapeutiques, des compositions pharmaceutiques, ainsi que des méthodes comprenant une région constante d'IgA. Les compositions et les méthodes de l'invention facilitent la liaison d'une construction d'anticorps comprenant un domaine constant IgA lié à CD47 et d'un antigène apparenté à une tumeur, tel que CD20 ou CD19.
Latest bibliographic data on file with the International Bureau